Spyre Therapeutics (SYRE) Stock Chart & Stock Price History $17.71 -0.29 (-1.61%) As of 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Spyre Therapeutics Stock Price Performance The Spyre Therapeutics (SYRE) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 52.14%, with a year-to-date return of -23.93%. In the past month, the stock has increased 18.62%, reflecting recent market activity. As of the latest close, Spyre Therapeutics traded at $18.00 with a market cap of $1.08 billion and volume of 568,825 shares. Receive SYRE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+4.36%1 Month Performance+18.62%3 Month Performance-6.20%Year-To-Date Performance-23.93%1 Year Performance-52.14% SYRE Stock Chart for Thursday, June, 12, 2025 SYRE Chart by TradingView Spyre Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/12/2025$18.00$17.71-1.61%$18.03$17.22887,318 shs$1.07 billion06/11/2025$18.56$18.00-3.02%$19.20$17.90568,825 shs$1.08 billion06/10/2025$17.16$18.56+8.16%$18.83$17.27460,769 shs$1.12 billion06/09/2025$16.97$17.16+1.12%$17.48$16.83422,397 shs$1.03 billion06/06/2025$16.62$16.97+2.11%$17.57$16.78309,214 shs$1.02 billion06/05/2025$16.52$16.62+0.61%$16.93$15.87357,659 shs$1.00 billion06/04/2025$16.57$16.52-0.30%$17.11$16.35453,626 shs$995.76 million06/03/2025$15.40$16.57+7.60%$16.72$15.39501,994 shs$998.77 million06/02/2025$15.25$15.40+0.98%$15.68$14.92381,326 shs$928.25 million05/30/2025$15.55$15.25-1.93%$15.50$14.75380,763 shs$919.21 million Get the Latest News and Ratings for SYRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/29/2025$15.08$15.55+3.12%$15.71$15.05299,321 shs$908.96 million05/28/2025$14.99$15.08+0.60%$15.38$14.87704,057 shs$908.96 million05/27/2025$15.01$14.99-0.13%$15.68$14.92435,228 shs$903.54 million05/26/2025$15.01$15.01$15.11$14.62210,288 shs$904.74 million05/23/2025$15.07$15.01-0.40%$15.11$14.62210,288 shs$904.74 million05/22/2025$14.78$15.07+1.96%$15.18$14.59358,047 shs$908.36 million05/21/2025$15.40$14.78-4.03%$15.45$14.65274,429 shs$890.88 million05/20/2025$14.88$15.40+3.49%$15.45$14.73297,273 shs$928.25 million05/19/2025$15.18$14.88-1.98%$15.55$14.61338,924 shs$896.91 million05/16/2025$14.54$15.18+4.40%$15.37$14.39340,714 shs$914.99 million05/15/2025$14.80$14.54-1.76%$14.86$14.12452,521 shs$876.41 million05/14/2025$14.75$14.80+0.34%$14.99$14.26907,797 shs$892.09 million05/13/2025$14.93$14.75-1.21%$14.96$14.131.03 million shs$889.07 million05/12/2025$14.10$14.93+5.89%$15.57$14.76663,378 shs$899.92 million Related Companies SRPT Stock Chart KRYS Stock Chart ACAD Stock Chart SWTX Stock Chart ZLAB Stock Chart RARE Stock Chart ACLX Stock Chart ALVO Stock Chart PTGX Stock Chart CPRX Stock Chart Receive SYRE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SYRE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
